Please tell us what you thought about today’s presentation by taking the survey below:
Join us for a PsychU webinar exploring unresolved symptoms in major depressive disorder (MDD) and the potential role of norepinephrine, as part of the monoaminergic theory of depression.
Despite the efficacy of first-line anti-depressant treatments in MDD, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine, a neurotransmitter which regulates concentration, energy levels, and arousal, may play a crucial role in the persistence of depression symptoms.2
Please join Drs. Roger McIntyre and John Awad as they discuss the potential role of norepinephrine in depression and the challenges of identifying and treating unresolved depression symptoms. Our webinar aims to provide valuable insights into the complex nature of depression and the potential for treatments to address unresolved symptoms of depression.
References:
Professor of Psychiatry and Pharmacology, University of Toronto, Head of the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada
Senior Medical Science Liaison
Speaker Roger S. McIntyre, MD, FRCPC is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker John Awad, MD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Notifications
